MC1 GBM patients in both the TCGA and CGGA cohorts were more sensitive to anti-PD1 therapies, with Bonferroni-corrected P values of 0.001 and 0.033, respectively, while MC2 GBM patients were more sensitive to anti-CTLA4 therapies, with Bonferroni-corrected P values of 0.019 and 0.047, respectively (Figure 6D and 6E). The gene discussed is CTLA4; the disease is glioblastoma.